Impact of aspirin on biochemical recurrence of prostate cancer after robot assisted radical prostatectomy in a multicenter retrospective cohort study

Impact of aspirin on biochemical recurrence of prostate cancer after robot assisted radical prostatectomy in a multicenter retrospective cohort study

Abstract This study evaluated the impact of aspirin on the biochemical recurrence (BCR) rate following robot-assisted radical prostatectomy (RARP) in patients. A database search identified patients who underwent RARP for pT2-3N0M0 disease at any of 25 centers between 2011 and 2022, categorized into...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuhei Suzuki, Hiromitsu Negoro, Masashi Kubota, Takayuki Sumiyoshi, Ryoichi Saito, Tomoya Okuno, Takehiko Segawa, Shigeki Fukuzawa, Hiroyuki Onishi, Kodai Hattahara, Kanji Nagahama, Yuya Sekine, Ryoma Kurahashi, Kimihiro Shimatani, Atsuro Sawada, Shusuke Akamatsu, Hiroyuki Nishiyama, Takayuki Goto, Takashi Kobayashi
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Aspirin
Biochemical recurrence
Prostate cancer
Robot-assisted laparoscopic radical prostatectomy
Survival rate
Online Access:https://doi.org/10.1038/s41598-025-86521-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study evaluated the impact of aspirin on the biochemical recurrence (BCR) rate following robot-assisted radical prostatectomy (RARP) in patients. A database search identified patients who underwent RARP for pT2-3N0M0 disease at any of 25 centers between 2011 and 2022, categorized into aspirin (n = 350) and control groups (n = 5857). Adjustment by 1:1 propensity score matching (PSM) and Mahalanobis distance matching (MDM) created 350 matched pairs. The effect of aspirin on the BCR rate was evaluated by analysis of BCR-free survival. After PSM and MDM, the 3-year BCR-free rate was significantly better in the aspirin group (85.0%, 95% confidence interval [CI] 80.8–89.4) than in the control group (PSM, 74.5%, 95% CI 66.5–83.5, p = 0.021; MDM, 74.7%, 95% CI 66.3–84.3, p = 0.037). In the analysis of high-risk subgroups, patients in the aspirin group with an ISUP (International Society of Urological Pathology) grade ≥ 4 had a significantly lower recurrence rate in both matched groups (PSM, hazard ratio 0.44, 95% CI 0.22–0.88; MDM, hazard ratio 0.45, 95% CI 0.23–0.90). In conclusion, this study suggests that aspirin could enhance BCR-free survival post-RARP, especially in patients with higher ISUP grades.
ISSN:2045-2322

Similar Items